+44 (0) 115 787 0500

Drug Development

With expertise in non-clinical and clinical development, and safety pharmacology assessments, that has been demonstrated through the registration of 16 new drugs, we have the expertise to provide our pharmaceutical and biotech clients the support to expedite, facilitate and optimise success in drug development.

Examples include supporting the development of lisdexamfetamine as a treatment for binge-eating disorder, and the abuse/dependence evaluations of this prodrug and of cannabidiol.

Our services include:

Our Expertise

Drug abuse and dependence

We have advised more than 50 clients on abuse/dependence evaluations for US, European and Japanese drug registrations. Our consultant scientists produce regulatory briefing documents, negotiate with regulators, and develop innovative experimental programs to assess abuse/dependence potential. We have performed regulatory abuse/dependence studies on more than 40 compounds.

CNS Disorders

We have over 30 years of experience in the development of treatments for psychiatric and neurological disorders including binge-eating disorder, ADHD, depression, anxiety, schizophrenia, epilepsy, pain, anaesthesia, and Parkinson’s and Alzheimer’s diseases.

Metabolic Disorders

We have extensive pre-clinical expertise in the development of treatment for obesity and its co-morbidities, and type 2 diabetes.


  • Research & Candidate Selection
  • Registration
  • Marketing

Get in touch to find out how we can help you.